GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally

The AAO will not be liable for loss or damage of any kind, including lost profits (whether or not the parties have been advised of such loss or damage) arising in any way with individuals or third-parties acts or omissions based on the foregoing AAO update.
Compared with full basal-bolus insulin regimens, the combination of GLP-1 agonist plus insulin resulted in a marginal 0.1% reduction in HbA1c, a 33% lower risk of hypoglycaemia and a mean 5.66-kg reduction in weight
Whats more, you can enjoy the added effects of this little miracle worker, including stress relief, decongestion, a skin glow and an improvement in your general well-being
Mol Neurobiol 55:69396955
After that, our maintenance injections are administered every one to three months for individuals with normal absorption